Abstract is: Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. It is metabolized by cytochrome P450 into 4-hydroxycyclophosphamide, which is then converted into aldophosphamide, which, in turn yields the cytotoxic metabolites and acrolein. Several Phase I trials have been completed.
| P233 | canonical SMILES | C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl |
| P231 | CAS Registry Number | 88859-04-5 |
| P661 | ChemSpider ID | 32697788 |
| P715 | DrugBank ID | DB12083 |
| P8494 | DSSTOX compound identifier | DTXCID401334175 |
| P3117 | DSSTox substance ID | DTXSID90905075 |
| P646 | Freebase ID | /m/02vvj1r |
| P234 | InChI | InChI=1S/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)/t9-,19-/m0/s1 |
| P235 | InChIKey | PBUUPFTVAPUWDE-UGZDLDLSSA-N |
| P2017 | isomeric SMILES | C1CO[P@@](=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCl)CCCl |
| P486 | MeSH descriptor ID | C048341 |
| P6366 | Microsoft Academic ID | 2776870398 |
| P11199 | Probes And Drugs ID | PD058687 |
| P662 | PubChem CID | 76968809 |
| P11089 | UniChem compound ID | 81785022 |
| P652 | UNII | 5970HH9923 |
| P527 | has part(s) | carbon | Q623 |
| phosphorus | Q674 | ||
| P366 | has use | medication | Q12140 |
| P2067 | mass | 399.985 | |
| P2868 | subject has role | immunologic adjuvant | Q967453 |
| antineoplastic | Q2853144 |
FileName: Mafosfamide-3D-balls.png
Description:
Ball-and-stick model of the mafosfamide molecule, an alkylating agent being investigated as an anti-cancer drug.
Colour code:
Work is copyrighted.
License: CC0
| Q70589449 | A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide) |
| Q61893860 | A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets |
| Q70374854 | ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows |
| Q69729345 | Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism |
| Q73130063 | Aldehyde dehydrogenase-mediated metabolism of acetaldehyde and mafosfamide in blood of healthy subjects and patients with malignant lymphoma |
| Q72047319 | Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging |
| Q70589445 | Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors |
| Q54483151 | Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors. |
| Q70589438 | Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro |
| Q40010617 | Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling |
| Q69961970 | Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models |
| Q72642608 | Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study |
| Q43720864 | Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group |
| Q72892161 | Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide |
| Q54269335 | Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma |
| Q68747664 | Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies |
| Q36606835 | Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide |
| Q70589461 | Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice |
| Q70589430 | Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide) |
| Q72750842 | Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission |
| Q57012928 | Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells |
| Q68242184 | Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557) |
| Q68100582 | Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation |
| Q69499290 | Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group |
| Q72822733 | Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions |
| Q53788375 | Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation |
| Q68672929 | Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557) |
| Q41297862 | Effects of Cisplatin and mafosfamide on the interphase microtubular cytoskeleton of a human breast-cancer cell-line, mx-1, in-vitro - a fine-structure and antitubulin immunofluorescence study. |
| Q68824896 | Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro |
| Q54401674 | Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). |
| Q44383731 | Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow |
| Q70589465 | Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice |
| Q69499722 | Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557) |
| Q68105009 | Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow |
| Q72120269 | Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide |
| Q43859030 | Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging |
| Q54279725 | Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment. |
| Q70589457 | Experimental toxicology of ASTA Z 7557 (INN mafosfamide) |
| Q69924344 | Fast hematological reconstitution after combined infusion of autologous bone marrow purged with mafosfamide and autologous peripheral blood stem cells in a patient with Ewing sarcoma |
| Q44617230 | Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors |
| Q73023192 | High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines |
| Q34111303 | Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide |
| Q40748405 | Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line |
| Q68697544 | In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213) |
| Q67789743 | In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor |
| Q70542012 | In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation |
| Q69749612 | In vitro reappearance of myeloid progenitors killed by mafosfamide |
| Q79335033 | In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone |
| Q70214472 | Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide |
| Q48415620 | Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination |
| Q45285640 | Intrathecal mafosfamide: a preclinical pharmacology and phase I trial |
| Q69531098 | Limiting dilution analysis for detection of residual leukemic cells after bone marrow combined decontamination with mafosfamide followed by merocyanine-540-mediated photosensitization |
| Q68774999 | Limiting-dilution analysis for the determination of leukemic cell frequencies after bone marrow decontamination with mafosfamide or merocyanine 540 |
| Q70174130 | Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide |
| Q70589443 | Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide) |
| Q41400708 | Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia |
| Q38023364 | Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials |
| Q71954342 | Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells |
| Q64389558 | Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes A possible mechanism of its immunosuppressive action |
| Q54333593 | Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow. |
| Q46761594 | Mafosfamide: a new intra-CSF chemotherapy? |
| Q85548825 | Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma |
| Q70638318 | Multiple chromosome abnormalities in patients with acute leukemia after autologous bone marrow transplantation using total body irradiation and marrow purged with mafosfamide |
| Q41331762 | Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow |
| Q50905173 | New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. |
| Q70135713 | Nigericin enhances mafosfamide cytotoxicity at low extracellular pH |
| Q72776729 | One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience |
| Q93896228 | Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide |
| Q68719561 | Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group |
| Q45230551 | Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). |
| Q36485382 | Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001) |
| Q71981646 | Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging |
| Q67939581 | Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine |
| Q54401049 | Preclinical and early clinical trial with mafosfamide as immune modulator. |
| Q70589453 | Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide) |
| Q68125053 | Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow |
| Q31962940 | Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications. |
| Q73784841 | Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells |
| Q54396311 | Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654). |
| Q69993048 | Regional fibrosis after intraperitoneal administration of mafosfamide |
| Q37706367 | Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells. |
| Q72839199 | Sensitivity of human CFU-GM to mafosfamide: analysis of the factors affecting individual variations |
| Q39190558 | Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells |
| Q68680881 | Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide |
| Q36745589 | Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells. |
| Q36732989 | Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z). |
| Q34287755 | Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines |
| Q39320933 | TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells. |
| Q77304841 | The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies |
| Q67997629 | The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells |
| Q69929237 | The kinetics of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (ASTA Z 7654) |
| Q70824508 | The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654) |
| Q69540115 | The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z) |
| Q70374857 | Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation |
| Q41161030 | Treatment with the anti-tumor drugs, cis-platin and mafosfamide, does not affect the structure of prekinetochores in a human breast cancer cell line. An immunofluorescence study using human anti-centromere autoantibodies |
| Q93525206 | [Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development] |
| Q72090389 | [Comparative study of mechanisms of antiproliferative action of low concentrations of mafosfamide and cyclosporin A] |
| Q70284169 | [Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia] |
| Category:Mafosfamide | wikimedia | |
| Mafosfamide | wikipedia | |
| Persian (fa / Q9168) | مافسفامید | wikipedia |
| Mafosfamida | wikipedia | |
| Мафосфамид | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Mafosfamid | wikipedia |
| Mafosfamid | wikipedia |
Search more.